Depósito pulmonar de partículas inhaladas

Tena, Ana Fernández; Clarà, Pere Casan

doi:10.1016/j.arbres.2012.02.003

Cited by 73 publications

(26 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on the particle size, three different mechanisms of drug deposition are defined, namely impaction, sedimentation and diffusion [16]. In impaction, the aerosol particles pass through the oropharynx and upper respiratory passages at a high velocity.…”

Section: Anatomy and Physiology Of The Lungsmentioning

confidence: 99%

“…The mucociliary movements clear the foreign particles immediately before they can move to lower areas of the lung by either coughing or swallowing [18,19]. The clearance in this region also depends on the number of cilia and the ciliary beat frequency, as well as the quality and quantity of mucus [16]. In the deeper areas of the lungs, i.e.…”

Section: Anatomy and Physiology Of The Lungsmentioning

confidence: 99%

“…The transporter proteins play a vital role in the transport of the API via active absorption or passive diffusion, depending on the nature and chemical structure of the API. Another important aspect in this region is the clearance of molecules by the alveolar macrophages, which needs to be taken into consideration in the drug transport mechanisms [16,19]. The molecules that are able to cross the barrier are either taken up by the cells and further absorbed into the systemic circulation or phagocytized by the alveolar macrophages.…”

Section: Anatomy and Physiology Of The Lungsmentioning

confidence: 99%

See 2 more Smart Citations

Nanoparticle-Mediated Pulmonary Drug Delivery: A Review

Paranjpe

Müller‐Goymann

2014

IJMS

374

217

View full text Add to dashboard Cite

Colloidal drug delivery systems have been extensively investigated as drug carriers for the application of different drugs via different routes of administration. Systems, such as solid lipid nanoparticles, polymeric nanoparticles and liposomes, have been investigated for a long time for the treatment of various lung diseases. The pulmonary route, owing to a noninvasive method of drug administration, for both local and systemic delivery of an active pharmaceutical ingredient (API) forms an ideal environment for APIs acting on pulmonary diseases and disorders. Additionally, this route offers many advantages, such as a high surface area with rapid absorption due to high vascularization and circumvention of the first pass effect. Aerosolization or inhalation of colloidal systems is currently being extensively studied and has huge potential for targeted drug delivery in the treatment of various diseases. Furthermore, the surfactant-associated proteins present at the interface enhance the effect of these formulations by decreasing the surface tension and allowing the maximum effect. The most challenging part of developing a colloidal system for nebulization is to maintain the critical physicochemical parameters for successful inhalation. The following review focuses on the current status of different colloidal systems available for the treatment of various lung disorders along with their characterization. Additionally, different in vitro, ex vivo and in vivo cell models developed for the testing of these systems with studies involving cell culture analysis are also discussed.

show abstract

Section: Anatomy and Physiology Of The Lungsmentioning

confidence: 99%

Section: Anatomy and Physiology Of The Lungsmentioning

confidence: 99%

Section: Anatomy and Physiology Of The Lungsmentioning

confidence: 99%

See 1 more Smart Citation

Nanoparticle-Mediated Pulmonary Drug Delivery: A Review

Paranjpe

Müller‐Goymann

2014

IJMS

374

217

View full text Add to dashboard Cite

show abstract

“…Those greater than 5–10 microns are less effective in transmission, generally falling to the ground with gravity or potentially being deposited in the most upper airways with close contact. In contrast, those 0.5 to 3–5 microns remain in still or turbulent air for 2–40 hours before settling onto a surface [1], are transmitted over a greater distance, and are more effectively inhaled into the tracheobronchial tree and alveolar space [3]. Laryngeal TB is thought to be particularly infectious [4], due to both the stimulus for cough and the capacity to generate transmissible M.tb droplets.…”

Section: Transmission and Establishment Of Infectionmentioning

confidence: 99%

“…nose, sinuses, pharynx, larynx, trachea, bronchi, bronchioles, and lungs); although it is unclear if these disease manifestations occur as a result of primary infection or reactivation locally or elsewhere. In order for M.tb to infect a cell in the alveolar space, it must navigate lung anatomy, airway function and the laws of physics that govern flow dynamics, size, shape, velocity, and number of inhaled particles [3]. For example, M.tb -containing droplets must evade cough reflex arcs, airway geometry, humidity, mucocilary clearance, and mucosal bactericidal compounds, etc.…”

Section: Mtb Transit Through the Respiratory Systemmentioning

confidence: 99%

Integrating Lung Physiology, Immunology, and Tuberculosis

Torrelles

Schlesinger

2017

Trends in Microbiology

110

101

View full text Add to dashboard Cite

Lungs are directly exposed to the air, have enormous surface area and enable gas exchange in air-breathing animals. They are constantly “attacked” by microbes from both outside and inside and thus possess a unique, highly regulated local immune defense system which efficiently allows for microbial clearance while minimizing damaging inflammatory responses. As a prototypic host-adapted airborne pathogen, Mycobacterium tuberculosis traverses the lung and has several ‘interaction points (IPs)’ which it must overcome to cause infection. These interactions are critical, not only from a pathogenesis perspective but also in considering the effectiveness of therapies and vaccines in the lungs. Here we discuss emerging views on immunologic interactions occurring in the lungs for M. tuberculosis and their impact on infection and persistence.

show abstract

Nanomaterials for Management of Lung Disorders and Drug Delivery

Menon¹,

Wadajkar²,

Xie³

et al. 2013

Nanomaterials in Drug Delivery, Imaging, and Tissue Engineering

View full text Add to dashboard Cite

There has been an increasing interest in pulmonary drug delivery and lung tissue regeneration to treat lung disorders in the past two decades. This route of administration is advantageous for both systemic as well as local drug delivery due to the large surface area available in the lung for drug absorption, higher permeability to solutes, and the noninvasive nature of treatment. Inhalational drug delivery is also highly beneficial for the diagnosis and treatment of lung diseases such as pulmonary arterial hypertension, cystic fibrosis, asthma, and lung cancer. Statistics show that lung cancer alone is responsible for nearly 1.3 million deaths worldwide every year, necessitating the need for alternative treatment methods, which can cure the disease while reducing discomfort to the patient. This chapter attempts to summarize the different types of nanoparticles (NPs) currently available for pulmonary drug delivery, the various targeting mechanisms for drug delivery and uptake, the applications of these NPs, and the current challenges faced in inhalational drug delivery. Further, the lung half-life of the NPs and their clearance rate from the lung following administration will also be discussed.

show abstract

Depósito pulmonar de partículas inhaladas

Cited by 73 publications

References 57 publications

Nanoparticle-Mediated Pulmonary Drug Delivery: A Review

Nanoparticle-Mediated Pulmonary Drug Delivery: A Review

Integrating Lung Physiology, Immunology, and Tuberculosis

Nanomaterials for Management of Lung Disorders and Drug Delivery

Contact Info

Product

Resources

About